Randomized, Placebo-Controlled Trial of Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2)


Study Overview

The CURB-2 Study is a phase 2, 8-week, randomized placebo controlled trial, studying the efficacy of a combination of extended-release Naltrexone and extended-release Buprenorphine compared to matched placebo injections for the treatment of cocaine use disorder (CUD). 

Study Product

The purpose of this study is to see if a combined treatment of injectable extended-release naltrexone (XR-NTX; Vivitrol®) and injectable extended-release Buprenorphine (XR-BUP; Sublocade®) are safe and effective for helping people cut down or stop using cocaine.

Eligibility

  • 18-65 years of age;
  • Interested in reducing or stopping cocaine use;
  • Be willing to comply with all study procedures and medication instructions.

Contact and Additional Information

CALL NOW: 424-325-9362